Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems

Not yet recruiting

• Conditions: HR-HPV Testing

• Registration Number: NCT06843720
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

To learn about the attitudes toward implementing self-collection among healthcare providers and staff, participants, and other stakeholders; and to inform the development of patient education and provider training materials to aid in the implementation of self-collection in clinical settings.

Detailed Description

The overarching goal of the implementation program is to increase cervical cancer screening, early detection, and linkage to treatment in underserved populations that receive care in safety net health systems. Specific goals are:

1. To increase up-to-date cervical cancer screening coverage by 10%;

2. To increase clinical encounters used for opportunistic cervical cancer screening using primary HR-HPV testing by 5% annually;

3. To increase awareness and readiness for implementing primary HR-HPV testing with self-sampling in routine care among clinics in the ECHO Network;

4. All patrticipants with abnormal screening results will be navigated to and receive diagnostic testing.

The overarching goal of program evaluation (i.e., research component of this protocol) is to evaluate the progress and achievement of program goals and to evaluate effectiveness and implementation outcomes:

Primary objective 1: Evaluate the effectiveness of primary HPV testing and self-collection to increase participation in cervical cancer screening among underscreened health system participants.

Primary objective 2: Evaluate implementation outcomes of the program across health systems and clinics and explore mechanisms underlying outcomes, guided by the Consolidated Framework for Implementation Research (CFIR)41,42 and RE-AIM (reach, effectiveness, adoption, implementation, maintenance)43.

Secondary Objectives Secondary objective 1: Compare the proportion of clinical encounters used for opportunistic cervical cancer screening across clinics.

Secondary objective 2: Evaluate proportion of participants receiving clinical follow-up after a positive HR-HPV test.

Secondary objective 3: Describe the prevalence of cervical cancer and pre-cancer among participants who self-collected and tested positive for HR-HPV.

Secondary objective 4: Compare the effectiveness of clinic-based primary HPV testing with self-collection with and without preceding telephone-based patient education by a participant navigator.

Study Timeline

• Status Verified: 2025-02
• Study First Submitted: 2025-02-19
• Study First Submitted QC: 2025-02-19
• Last Update Submitted: 2025-02-19
• Study First Posted: 2025-02-25
• Last Update Posted: 2025-02-25
• Study Start: 2025-08-31
• Primary Completion: 2029-03-31
• Study Completion: 2031-03-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 7100

Inclusion Criteria

Populations involved in the research are: 1) stakeholder advisory board members; 2) Participants eligible for cervical cancer screening participating in the cluster randomized stepped-wedge trial; 3) Patients and community members participating in formative research activities; 4) Investigators, clinic staff, and other health system stakeholders from partnering health systems; 5) Project ECHO Participants (providers, clinic staff, and other health system stakeholders from partner and non-partner institutions).

The eligibility criteria for each are:

Participants eligible for cervical cancer screening:

• Currently a resident in the state of Texas
• Attend for care at a partner clinic enrolled in the study
• Women and persons with a cervix
• Age 25-65
• Due or past due for cervical cancer screening

Participants and community members participating in formative research activities:

• Purposively identified as a stakeholder for formative research by research staff Investigators, clinic staff, and other health system stakeholders from partnering health systems:
• Employed at least part-time by a partnering health system
• Age 18+

Project ECHO Participants:

• Participate in at least one Project ECHO session
• Age 18+

Exclusion Criteria

Participants eligible for cervical cancer screening:

• Report being currently pregnant
• History of total hysterectomy
• History of cervical cancer

Other study populations:

• Unable to communicate in English or Spanish

Vulnerable Populations Participants/samples belonging to vulnerable populations (children, pregnant women, cognitively impaired adults, or prisoners) will be prohibited from participation.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety and Adverse Events (AEs). Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03	Through study completion; an average of 1 year.

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States